MALSU1 and neoplasm: In summary, individual silencing of either MALSU1 or TMEM261 each significantly impacted tumor progression in vivo, with differential effects on primary and metastatic progression, revealing that tumors in different locations differ in their metabolic requirements (Fig 4R).